"10.1371_journal.pone.0017874","plos one","2011-03-15T00:00:00Z","C Andrew Boswell; Gregory Z Ferl; Eduardo E Mundo; Daniela Bumbaca; Michelle G Schweiger; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli","Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech Inc., South San Francisco, California, United States of America; Department of Investigative Safety Assessment, Genentech Inc., South San Francisco, California, United States of America","Conceived and designed the experiments: CAB MGS F-PT PJF LAK. Performed the experiments: CAB GZF EEM DB MGS. Analyzed the data: CAB GZF EEM DB MGS F-PT PJF LAK. Contributed reagents/materials/analysis tools: CAB GZF EEM DB MGS. Wrote the paper: CAB GZF EEM DB MGS F-PT PJF LAK.","The authors have read the journals policy and have the following conflicts: All authors are paid employees of Genentech, a member of the Roche Group, and hold financial interest in Roche in the form of stocks and/or options. Two drugs mentioned in this manuscript, trastuzumab and bevacizumab, are marketed by Genentech/Roche. In addition, CAB serves as an Academic Editor for PLoS ONE. None of these financial or competing interests alters the authors adherence to all PLoS ONE policies on sharing data and materials.","2011","03","C Andrew Boswell","CAB",8,TRUE,5,5,8,8,TRUE,TRUE,FALSE,0,NA,FALSE
